tetano
Editor, Senior Moderator
Am J Transplant
. 2020 Jun 1.
doi: 10.1111/ajt.16089. Online ahead of print.
Renal Infarct in a COVID-19 Positive Kidney-Pancreas Transplant Recipient
Jieqing Jessica Xu[SUP] 1 [/SUP], Daniel Samaha[SUP] 2 [/SUP], Suhas Mondhe[SUP] 2 [/SUP], David Massicotte-Azarniouch[SUP] 2 [/SUP], Gregory Knoll[SUP] 2 3 [/SUP], Marcel Ruzicka[SUP] 2 3 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) is associated with increased risk of thromboembolic events, but the extent and duration of this hypercoagulable state remains unknown. We describe the first case report of renal allograft infarction in a 46-year-old kidney-pancreas transplant recipient with no prior history of thromboembolism, who presented 26 days after diagnosis of COVID-19. At the time of renal infarct, he was COVID-19 symptom free and repeat test for SARS-CoV-2 was negative. This case report suggests that a hypercoagulable state may persist even after resolution of COVID-19. Further studies are required to determine thromboprophylaxis indications and duration in solid organ transplant recipients with COVID-19.
. 2020 Jun 1.
doi: 10.1111/ajt.16089. Online ahead of print.
Renal Infarct in a COVID-19 Positive Kidney-Pancreas Transplant Recipient
Jieqing Jessica Xu[SUP] 1 [/SUP], Daniel Samaha[SUP] 2 [/SUP], Suhas Mondhe[SUP] 2 [/SUP], David Massicotte-Azarniouch[SUP] 2 [/SUP], Gregory Knoll[SUP] 2 3 [/SUP], Marcel Ruzicka[SUP] 2 3 [/SUP]
Affiliations
- PMID: 32483909
- DOI: 10.1111/ajt.16089
Abstract
The novel coronavirus disease 2019 (COVID-19) is associated with increased risk of thromboembolic events, but the extent and duration of this hypercoagulable state remains unknown. We describe the first case report of renal allograft infarction in a 46-year-old kidney-pancreas transplant recipient with no prior history of thromboembolism, who presented 26 days after diagnosis of COVID-19. At the time of renal infarct, he was COVID-19 symptom free and repeat test for SARS-CoV-2 was negative. This case report suggests that a hypercoagulable state may persist even after resolution of COVID-19. Further studies are required to determine thromboprophylaxis indications and duration in solid organ transplant recipients with COVID-19.